Itraconazol no tratamento da pitiríase versicolor: comparação entre 5 e 7 dias de tratamento

Cucé, Luiz Carlos; Belda, Walter; Ribeiro, Eliane Barbosa de Oliveira

doi:10.1590/s0036-46651990000300006

Cited by 9 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The minimum cumulative dose for itraconazole is 1000 mg, although an improved efficacy is more likely to occur with the regimen of 200 mg/d for 7 days 196 Table 2. summarizes the randomized clinical trials that have been conducted using itraconazole to treat pityriasis versicolor 197–211 …”

Section: Treatmentmentioning

confidence: 99%

Pityriasis versicolor

Gupta

Bluhm

Summerbell

2002

Acad Dermatol Venereol

143

165

View full text Add to dashboard Cite

show abstract

Section: Treatmentmentioning

confidence: 99%

Pityriasis versicolor

Gupta

Bluhm

Summerbell

2002

Acad Dermatol Venereol

143

165

View full text Add to dashboard Cite

show abstract

“…Fluconazole, ketoconazole and itraconazole are the preferred oral agents. 16 Various dosing regimens have been used. Itraconazole is usually given at 200mg/d for 5, 7 or 10 days, 400mg/day for 3 days and 400mg/day for 1 day.…”

Section: 5mentioning

confidence: 99%

A comparative study of oral Ketoconazole versus Itraconazole in the treatment of Tinea versicolor

et al. 2021

View full text Add to dashboard Cite

Tinea (pityriasis) versicolor is a superficial fungal infection and one of the most commonly found pigmentary disorders of the skin caused by the yeast Malassezia. Multiple topical as well as systemic therapies are available for treatment. Systemic therapies are used for extensive disease, frequent relapse or where topical agents have failed. The aim that translates the rationale of the study was to compare the efficacy, safety, tolerability and cost effectiveness of oral ketoconazole dose 200mg daily for 7 days versus a single dose of 400 mg of itraconazole in the treatment of tinea versicolor. A total of 64 patients (aged 18-50 years) were selected for the study from the period of June 2019 to November 2019 in the Department of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University, Bangladesh. Cases having extensive involvement were diagnosed clinically and confirmed by wood's lamp and KOH microscopy was taken. Patients were randomly allocated into equal groups. Group A was given oral ketoconazole dose 200mg daily for 7 days and Group B has given a single dose of 400 mg of itraconazole. 47 (73.4%) male and 17(26.6%) female were included in the study. The mean age of group A was 29.2(SD±8.6) and in group B 28.2(SD±8.5) years. The mean duration of the disease in group A was 3.9(±2.7) months and 3.5(±2.2) months in group B. In group A clinical responders was found cure 25(78.1%), improvement 5(15.6%) and failure in 2(6.2%) and in group B it was found cure 22(68.8%), improvement 7(21.87%) and failure 3(9.4%) at one month. At two months in the group A clinical responder was found to cure 22(68.8%), improvement 5(15.6%), failure in 3(9.4%) and relapse 2(6.2%). In group B it was found cure 18(56.2%), improvement 6(18.75%), failure 4(12.5%) and relapse 4(12.5%). Both oral ketoconazole dose 200mg daily for 7 days versus single dose 400 mg of itraconazole can be effective in the treatment of tinea versicolor with extensive involvement. CBMJ 2020 July: Vol. 09 No. 02 P: 26-33

show abstract

“…Three oral azoles, ketoconazole (30), itraconazole (19), and fluconazole (10) were given in widely varied regimens in 18 CCTs (N = 1643). An oral azole was compared with placebo (2 CCTs; n = 49); 64,65 another oral azole (3 CCTs; n = 230), [66][67][68] or another dosing regimen (13 CCTs; n = 1364) [69][70][71][72][73][74][75][76][77][78][79][80][81] (Tables S7 to S9). Thirty-eight single-arm trials (SATs) were included and used ketoconazole (22), [82][83][84][85][86][87][88][89][90][91][92][93][94][95][96][97][98][99][100][101] itraconazole (9), [102][103][104][105][106][107][108][109]…”

Section: Description Of Included Studiesmentioning

confidence: 99%

“…Among nine CCTs that had events, only six (n=324) contributed data but could not be pooled. There was no significant difference in clinical adverse effects in individual studies that compared triazole vs ketoconazole, 66 fluconazole vs itraconazole, 68 divided daily dose vs single daily dose, 74 10day vs 20-day ketoconazole, 78 5-vs 7-day itraconazole, 81 and 5-vs 10-and 15-day itraconazole 80 (Table S11).…”

Section: Effects Of Interventions (Nrs): Adverse Effect Outcomesmentioning

confidence: 99%

Systematic Review and Meta-analysis on Oral azoles for the Treatment of Pityriasis Versicolor

Flores-Genuino¹,

Dofitas²,

Dans³

et al. 2019

Acta Med Philipp

View full text Add to dashboard Cite

Background. Oral azole drugs are a second-line option for the treatment of pityriasis versicolor but evidence on their efficacy and safety is unclear. Objectives. To determine the efficacy and safety of oral azoles in the treatment of patients with pityriasis versicolor. Methods: We searched MEDLINE, CENTRAL, EMBASE, LILACS, and HERDIN, from inception to the period between January to February 2014. We did not restrict the search by language or publication status.We included randomized controlled trials (RCTs) that compared the efficacy of oral azoles with placebo or no treatment, with topical agents, other oral azoles or dosing regimens in the treatment of pityriasis versicolor, and that measured any of the pre-specified outcomes (mycologic cure, clinical cure, recurrence, duration to cure, timeto-cure, and quality of life). For adverse effects, we also included non-randomized studies (NRS). We used Cochrane methods to select studies, extract data, assess risk of bias, pool studies, and calculate for treatment effects. Results. We included 38 RCTs (n=2894) and 56 NRS (n=3452). Overall, there were few pooled studies and evidence was low to moderate quality. Oral azoles were more effective than placebo (mycologic cure, RR 11.34, 95% CI 4.90, 26.28; 3 RCTs, n=131; I2=0%; low quality of evidence) and as effective as topical agents (mycologic cure, RR 1.02, 95% CI 0.86, 1.21; 4 RCTs, n=232; I2=60%; moderate quality of evidence).There were few adverse effects and were mostly minor and transient. Conclusions. Oral azoles may be more effective than placebo, and are probably as effective as topical agents in the treatment of PV. Triazoles are probably as effective as ketoconazole. Adverse effects were few, mostly minor, and transient.

show abstract

Itraconazol no tratamento da pitiríase versicolor: comparação entre 5 e 7 dias de tratamento

Cited by 9 publications

References 8 publications

Pityriasis versicolor

Pityriasis versicolor

A comparative study of oral Ketoconazole versus Itraconazole in the treatment of Tinea versicolor

Systematic Review and Meta-analysis on Oral azoles for the Treatment of Pityriasis Versicolor

Contact Info

Product

Resources

About